NGM Biopharmaceuticals, Inc. (NGM)의 가격은 얼마입니까?

NGM Biopharmaceuticals, Inc. (NGM)의 가격은 $1.54입니다.

NGM Biopharmaceuticals, Inc. (NGM)의 시가 총액은 무엇입니까?

NGM Biopharmaceuticals, Inc. (NGM)의 시가 총액은 $119.21M입니다.

NGM Biopharmaceuticals, Inc. (NGM) 영업이익률

NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.

연도	영업이익률	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

영업이익률

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	영업이익률	영업이익률 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Moderna, Inc. MRNA.US	-149.01%	-	US
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH

회사

영업이익률

영업이익률 차이

국가